UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 808

Sortiert nach

Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (4), p.394-409

2018

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

Clinical pharmacology and therapeutics, 2013-04, Vol.93 (4), p.324-325

2013

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

Clinical pharmacology and therapeutics, 2011-03, Vol.89 (3), p.387-391

2011

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

Gut, 2009-07, Vol.58 (7), p.940-948

2009

Volltextzugriff (PDF)

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Alimentary pharmacology & therapeutics, 2015-01, Vol.41 (1), p.77-86

2015

Volltextzugriff (PDF)

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

Alimentary pharmacology & therapeutics, 2015-11, Vol.42 (10), p.1200-1210

2015

Volltextzugriff (PDF)

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

Alimentary pharmacology & therapeutics, 2002-01, Vol.16 (1), p.51-60

2002

Volltextzugriff (PDF)

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Gut, 2005-01, Vol.54 (1), p.91-96

2005

Volltextzugriff (PDF)

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.617-630

2017

Volltextzugriff (PDF)

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease

Alimentary pharmacology & therapeutics, 2013-08, Vol.38 (3), p.255-263

2013

Volltextzugriff (PDF)

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Alimentary pharmacology & therapeutics, 2014-10, Vol.40 (8), p.903-916

2014

Volltextzugriff (PDF)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

Alimentary pharmacology & therapeutics, 2013-11, Vol.38 (10), p.1236-1247

2013

Volltextzugriff (PDF)

One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

Alimentary pharmacology & therapeutics, 2013-01, Vol.37 (2), p.204-213

2013

Volltextzugriff (PDF)

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo‐controlled study

Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (2), p.185-193

2011

Volltextzugriff (PDF)

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Alimentary pharmacology & therapeutics, 2014-05, Vol.39 (10), p.1126-1135

2014

Volltextzugriff (PDF)

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

Gut, 2006-11, Vol.55 (11), p.1561-1567

2006

Volltextzugriff (PDF)

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Alimentary pharmacology & therapeutics, 2009-08, Vol.30 (3), p.210-226

2009

Volltextzugriff (PDF)

Review article: biological activity markers in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2007-02, Vol.25 (3), p.247-255

2007

Volltextzugriff (PDF)

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis

Alimentary Pharmacology & Therapeutics (Suppl), 2017-04, Vol.45 (8), p.1058-1072

2017

Volltextzugriff (PDF)

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease

Alimentary pharmacology & therapeutics, 2005-03, Vol.21 (6), p.733-738

2005

Volltextzugriff (PDF)

Systematic review: the management of pouchitis

Alimentary pharmacology & therapeutics, 2006-04, Vol.23 (8), p.1087-1096

2006

Volltextzugriff (PDF)

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Gut, 2004-10, Vol.53 (10), p.1485-1493

2004

Volltextzugriff (PDF)

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.447-459

2013

Volltextzugriff (PDF)

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1296-1309

2010

Volltextzugriff (PDF)

1 – 25 von 808

Suche als RSS-Feed

Aktive Filter

PublikationsformBerichte

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(780)
Mit Volltextzugriff
(664)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(377)
Life Sciences & Biomedicine
(372)
Humans
(367)
Gastroenterology & Hepatology
(318)
Female
(232)
Adult
(231)
Male
(231)
Middle Aged
(192)
Biological And Medical Sciences
(175)
Medical Sciences
(175)
Aged
(118)
Gastroenterology. Liver. Pancreas. Abdomen
(108)
Crohn Disease - Drug Therapy
(106)
Treatment Outcome
(102)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(101)
Inflammatory Bowel Disease
(100)
Other Diseases. Semiology
(99)
Adolescent
(94)
Pharmacology & Pharmacy
(91)
Crohn's Disease
(84)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Adalimumab for the treatment of fistulas in patients with Crohn’s disease

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo‐controlled study

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Review article: biological activity markers in inflammatory bowel disease

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease

Systematic review: the management of pouchitis

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Aktive Filter

Suchergebnisse filtern